Skip to main content
Terug
IOVA logo

Iovance Biotherapeutics, Inc.

Datakwaliteit: 100%
IOVA
NASDAQ Healthcare Biotechnology
€ 3,62
▼ € 0,01 (-0,28%)
Marktkapitalisatie: 1,20B
Dagbereik
€ 3,43 € 3,68
52-Weeksbereik
€ 1,64 € 5,63
Volume
11.794.990
50D / 200D Gem.
€ 3,20 / € 2,53
Vorige Slotkoers
€ 3,63

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -3,1 0,3
P/B 1,7 2,9
ROE % -55,5 3,7
Net Margin % -148,4 3,8
Rev Growth 5Y % 10,0
D/E 0,1 0,2

Koersdoel Analisten

Hold
€ 2,00 -44.8%
Forward WPA
-€ 0,50
Omzet Sch.
380 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 0,22
€ 0,18 – € 0,27
870 M 2
FY2029 € 0,10
€ 0,08 – € 0,13
790 M 4
FY2028 € 0,01
-€ 0,11 – € 0,19
740 M 6

Belangrijkste Punten

Debt/Equity of 0,07 — conservative balance sheet
Negative free cash flow of -336,24M
PEG of 0,17 suggests growth is underpriced

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)60,60%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-55,50%
ROIC-40,50%
Net Margin-148,38%
Op. Margin-153,08%

Veiligheid

Debt / Equity
0,07
Current Ratio3,20
Interest Coverage0,00

Waardering

P/E Ratio
-3,07
P/B Ratio1,72
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 60,60% Revenue Growth (3Y) 1388,68%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 263,50M Net Income (TTM) -390,98M
ROE -55,50% ROA -42,82%
Gross Margin 97,23% Operating Margin -153,08%
Net Margin -148,38% Free Cash Flow (TTM) -336,24M
ROIC -40,50% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,07 Current Ratio 3,20
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -3,07 P/B Ratio 1,72
P/S Ratio 4,56 PEG Ratio 0,17
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,20B Enterprise Value 1,09B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 263,50M 164,07M 1,19M 0,0 0,0
Net Income -390,98M -372,18M -444,04M -395,89M -342,25M
EPS (Diluted) -1,09 -1,28 -1,89 -2,49 -2,23
Gross Profit 256,22M 40,08M -9,57M 0,0 0,0
Operating Income -403,36M -395,28M -460,56M -398,88M -342,70M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 913,17M 910,43M 780,35M 663,98M 777,33M
Total Liabilities 214,59M 200,02M 195,74M 164,34M 155,67M
Shareholders' Equity 698,58M 710,41M 584,61M 499,64M 621,66M
Total Debt 48,44M 58,26M 75,86M 85,45M 71,53M
Cash & Equivalents 163,08M 115,69M 114,89M 231,73M 78,23M
Current Assets 442,69M 457,02M 307,85M 479,12M 507,96M
Current Liabilities 138,36M 122,34M 110,31M 91,49M 89,20M